VioQuest Pharmaceuticals Stock Forecast, Price & News

0.00 (-1.22 %)
(As of 06/9/2021)
Today's Range
50-Day Range
52-Week Range
Volume100 shs
Average Volume11,382 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VOQP News and Ratings via Email

Sign-up to receive the latest news and ratings for VioQuest Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About VioQuest Pharmaceuticals

VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products' lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.


No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.00 out of 5 stars

Medical Sector

1973rd out of 2,099 stocks

Pharmaceutical Preparations Industry

805th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

VioQuest Pharmaceuticals (OTCMKTS:VOQP) Frequently Asked Questions

What stocks does MarketBeat like better than VioQuest Pharmaceuticals?

Wall Street analysts have given VioQuest Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VioQuest Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are VioQuest Pharmaceuticals' key executives?

VioQuest Pharmaceuticals' management team includes the following people:
  • Dr. Yaping Hong, Sr. VP of Global Process R&D (Age 65, Pay $192.22k)
  • Mr. Mark D. Dacko, Controller and Assistant Sec. (Age 70)
  • Dr. Michael Cannarsa Ph.D., Gen. Mang. of Chiral Quest (Age 64)

Who are some of VioQuest Pharmaceuticals' key competitors?

What is VioQuest Pharmaceuticals' stock symbol?

VioQuest Pharmaceuticals trades on the OTCMKTS under the ticker symbol "VOQP."

How do I buy shares of VioQuest Pharmaceuticals?

Shares of VOQP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VioQuest Pharmaceuticals' stock price today?

One share of VOQP stock can currently be purchased for approximately $0.01.

How many employees does VioQuest Pharmaceuticals have?

VioQuest Pharmaceuticals employs 3 workers across the globe.

What is VioQuest Pharmaceuticals' official website?

The official website for VioQuest Pharmaceuticals is www.vioquestpharm.com.

Where are VioQuest Pharmaceuticals' headquarters?

VioQuest Pharmaceuticals is headquartered at 180 MT. AIRY ROAD SUITE 102, BASKING RIDGE NJ, 07920.

How can I contact VioQuest Pharmaceuticals?

VioQuest Pharmaceuticals' mailing address is 180 MT. AIRY ROAD SUITE 102, BASKING RIDGE NJ, 07920. The company can be reached via phone at 908-766-4455.

This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.